Form 6K NuCana plc For: 8 June
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
NuCana PLC ADR (NCNA)
NuCana PLC ADR stock price live, this page displays NASDAQ NCNA stock exchange data. View the NCNA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the NuCana PLC ADR real time stock price chart below.
What Is the NuCana PLC ADR Stock Price Today?
The NuCana PLC ADR stock price today is 1,100.
What Is the Stock Symbol for NuCana PLC ADR?
The stock symbol for NuCana PLC ADR is "NCNA."
What Stock Exchange Does NuCana PLC ADR Trade On?
NuCana PLC ADR is listed and trades on the NASDAQ stock exchange.
Is NuCana PLC ADR a Good Stock to Buy?
Determining whether NuCana PLC ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NCNA quote. (ISIN: US67022C3043)
What Is the NuCana PLC ADR Stock Price Today?
The NuCana PLC ADR stock price today is 1,100.
What Is the Stock Symbol for NuCana PLC ADR?
The stock symbol for NuCana PLC ADR is "NCNA."
What Stock Exchange Does NuCana PLC ADR Trade On?
NuCana PLC ADR is listed and trades on the NASDAQ stock exchange.
Is NuCana PLC ADR a Good Stock to Buy?
Determining whether NuCana PLC ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NCNA quote. (ISIN: US67022C3043)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.070
1.180
52 wk Range
0.948
6.160
NCNA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.0701.180
52 wk Range
0.9486.160
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NCNA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Form 6K NuCana PLC For: 1 June- Investing.com
Form 6K NuCana plc For: 6 May- Investing.com
NuCana names Ian Webster as chief financial officer- Investing.com
- Form 6K NuCana plc For: 8 June
- Investing.com
- Form 6K NuCana PLC For: 1 June
- Investing.com
- NuCana names Ian Webster as chief financial officer
- Investing.com
NuCana names Ian Webster as chief financial officer- Investing.com
- Form 6K NuCana PLC For: 14 May
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Earnings
Latest Release
Aug 13, 2026
EPS / Forecast
-- / -2,00
Revenue / Forecast
-- / --
Compare NCNA to Peers and Sector
Metrics to compare | NCNA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNCNAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.4x | −6.3x | −0.3x | |
PEG Ratio | 0.00 | −0.46 | 0.00 | |
Price/Book | 0.2x | 3.6x | 2.6x | |
Price / LTM Sales | - | 4.1x | 3.0x | |
Upside (Analyst Target) | - | 247.7% | 61.2% | |
Fair Value Upside | Unlock | 12.8% | 7.2% | Unlock |
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It also developing NUC-7738, a ProTide transformation of 3’-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. It has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the NuCana ADR (NCNA) Stock Price Today?
The NuCana ADR stock price today is 1,100 USD.
What Stock Exchange Does NuCana ADR Trade On?
NuCana ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for NuCana ADR?
The stock symbol for NuCana ADR is "NCNA."
What Is the NuCana ADR Market Cap?
As of today, NuCana ADR market cap is 4,740M USD.
What Is NuCana ADR's Earnings Per Share (TTM)?
The NuCana ADR EPS (TTM) is -2,389.
When Is the Next NuCana ADR Earnings Date?
NuCana ADR will release its next earnings report on Nov 12, 2026.
From a Technical Analysis Perspective, Is NCNA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has NuCana ADR Stock Split?
NuCana ADR has split 2 times.
How Many Employees Does NuCana ADR Have?
NuCana ADR has 11 employees.
What is the current trading status of NuCana ADR (NCNA)?
As of Oct 11, 2026, NuCana ADR (NCNA) is trading at a price of 1,100 USD, with a previous close of 1,100 USD. The stock has fluctuated within a day range of 1,070 USD to 1,180 USD, while its 52-week range spans from 0,948 USD to 6,160 USD.
What Is the NCNA Premarket Price?
NCNA's last pre-market stock price is 1,106 USD. The pre-market share volume is 4 530,000, and the stock has decreased by -0,024, or -2,120%.
What Is the NCNA After Hours Price?
NCNA's last after hours stock price is 1,091 USD, the stock has decreased by -0,009, or -0,830%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.